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Objective: The objectives of this study were to: 1) examine the psychometric properties of
three shortened versions of the Asthma Control Questionnaire (ACQ) and their comparative
performance with the original 7-item ACQ in persistent asthma patients; and 2) explore the
concordance of asthma control outcomes from the four versions of the ACQ when compared
with international guidelines for asthma control.
Method: Post-hoc analyses of two large (nZ 737 and nZ 772) Phase III, randomized, double-
blind, parallel-group, multi-center placebo-controlled studies of mometasone furoate/formo-
terol fumarate combination formulation compared with monotherapies in subjects with persis-
tent asthma previously treated with low-dose or medium-dose inhaled glucocorticoids. This
study examined the psychometric performance of the four ACQ versions and the concordance
between these four versions with each other and international guidelines.
Results: The psychometric results for all four versions of the ACQ were robust, with Cronbach
alphas 0.82 and test-retest ICCs  0.75. All versions of the ACQ were strongly correlated with
each other (r  0.97), as well the overall score from the AQLQ12þ for both baseline and
change scores (jrj  0.74). When the four ACQ versions were compared to each other, both
cross sectional and longitudinal change concordances were mostly substantial, but agreements
were lower when compared to international guidelines classifications.
Conclusion: All ACQ versions have similar and strong psychometric properties. Classifications of
change over time using the original ACQ and a six-item version without SABA use provided gener-
ally fair to moderate agreement with the international guidelines criteria for asthma control.
ª 2011 Elsevier Ltd. All rights reserved.4 773 8000; fax: þ1 314 773 8004.
itedbiosource.com (K.W. Wyrwich).
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concordance of patient control outcomes across the fourDespite the availability of effective treatments, asthma
continues to be one of the most costly and burdensome
chronic disorders in the United States, ranking third
behind myocardial infarction and congestive heart failure
in prevalence and fourth in terms of annual per capita
direct costs.22 Uncontrolled asthma resulting in asthma
exacerbations drives these costs, and leads to more clinic
and emergency department visits, hospitalizations, and
resulting direct and indirect expenses.22
Asthma control, as a patient-reported outcome, can
be measured by administration of many validated
instruments.7,14e16,20 Of these, the Asthma Control Ques-
tionnaire (ACQ) was developed and validated by Juniper and
colleagues7 and has demonstrated reliability, validity, and
sensitivity to change.1,2,4,9,21 The ACQ is comprised of 7
items each measured on a 7-point response scale: five items
that measure the frequency, intensity or limitations from
asthma symptoms using one week recall, one item that scores
the average number of daily puffs needed from a short-acting
beta agonist (SABA) bronchodilator during the past week, and
a final clinic-assessed item scoring FEV1% predicted.
7 The
overall score is the mean of the item responses and ranges
from 0 (totally controlled) to 6 (severely uncontrolled).
In 2005, Juniper and colleagues investigated the measure-
ment properties, including change over time, of three short-
ened versions of the ACQ: 1) a five-item measure using only
the symptoms items (hereafter referred to as the ACQ-5);
six-item measure that excluded the average daily SABA
use item from the original seven items (hereafter referred
to as the ACQ-6a) and another six-item measure that
excluded the FEV1% predicted item from the original seven
items (hereafter referred to as the ACQ-6b).9 These
researchers concluded that themeasurement propertieswere
very similar for all four versions of the ACQ (original 7-item
ACQ and three shortened versions), and “the minimum
important difference for all versions was close to 0.50”.9
Juniper and colleagues11 also investigated the ACQ
score that identifies the best cut point where patients
cross over from being well-controlled to not well-controlled
using the 7-item ACQ, as well as the ACQ-6b and ACQ-5
versions. Using ACQ scores that jointly optimized positive-
and negative-predicted values from asthma patients clas-
sified as “well controlled” using a composite algorithm
based on the Global Initiative of Asthma (GINA) and
National Institutes of Health (NIH) guidelines using data
collected in the clinical trials diaries and clinic records, the
crossover score of 1.00 was acknowledged as the best single
cut point for the three tested versions of the ACQ.11
This study examined whether the shortened versions of
the ACQ have comparative performance with the 7-item ACQ
in persistent asthma patients using data collected in two
large Phase III, randomized, double-blind, parallel-group,
multi-center placebo-controlled efficacy and safety studies
of mometasone furoate/formoterol fumarate combination
formulation compared with monotherapies in subjects with
persistent asthma previously treated with: 1) low-dose or 2)
medium-dose inhaled glucocorticoids. The comparative
psychometric properties (reliability, validity, and respon-
siveness) of the four versions were examined, as well as theversions using the 1.00 cut point. As a secondary objective,
concordance of asthma control outcomes from the four
versions of the ACQ were compared with the current GINA
and the National Heart, Blood and Lung Institute (NHBLI) of
the NIH classifications of asthma control using the daily diary
data collected during the clinical trials.
Methods
Data sources and study populations
Psychometric properties and control-related concordance
were investigated using post-hoc analyses from two large
Phase III multi-center, randomized, double-blind, placebo-
controlled, clinical trials of mometasone furoate/for-
moterol fumarate (MFF) 100/10 mg (mcg) twice-daily or
200/10 mcg twice-daily compared with mometasone furo-
ate (MF) and formoterol (F) monotherapies and placebo in
subjects with persistent asthma previously treated with
low-dose or medium-dose inhaled glucocorticosteroids,
hereafter referred to as the low-dose study (NCT00383552)
or medium-dose study (NCT00383240), respectively. The
treatment period after randomization was 26 weeks and
the 7-item ACQ, along with the 32-item Asthma Quality of
Life Questionnaire with Standardized Activities for persons
age 12 years and older (AQLQ12þ), were administered via
pencil and paper to subjects at baseline and Weeks 4, 12
and 26 (end of treatment).
Eligible trial participants met the following inclusion
criteria for both studies: 1) age 12 years or older with
a diagnosis of asthma of at least 12 months duration based
on clinical history, examination, pulmonary function, and
response to b2 agonists; 2) low- or medium-dose daily use
of ICS, respectively, either alone or in combination with
long-acting b2 agonists (LABA) for at least 12 weeks at
a stable dose at least two weeks prior to screening; 3) no
inherent harm in changing the subjects current asthma
therapy and the willingness of the participant to dis-
continue prescribed ICS or ICS/LABA prior to study drug
run-in as judged by the investigator; 4) demonstrated
increase in absolute FEV1 of at least 12% and a volume
increase of at least 200 mL 15e20 min after administration
of 4 inhalations of albuterol/salbutamol or PEF variability
of more than 20% expressed as a percentage of the mean
highest and lowest morning pre-bronchodilator PEF over
at least 1 week or demonstrate diurnal variation PEF of
more than 20% based on the difference between pre-
bronchodilator morning value and the post-bronchodilator
value from the evening before; 5) FEV1 must be 60% and
90% predicted; 6) baseline FEV1 must be 60% and 85%
predicted when all restricted medications have been
withheld for the appropriate intervals; 7) acceptable
laboratory tests (CBC, chemistry, serum pregnancy for
females), ECG, and chest x-ray; 8) willingness to provide
written informed consent/assent (or had a legal guardian
for adolescents).
Smokers (current or past) were ineligible for these trials
if their lifetime smoking history exceeded 10 pack-years.
Additional exclusion criteria included having another respi-
ratory condition (chronic obstructive pulmonary disease
700 K.W. Wyrwich et al.(COPD), emphysema, bronchiectasis, cystic fibrosis) or
being positive for Human Immunodeficiency Virus (HIV).
Further, participants were prohibited from using any of
the following medications without the appropriate
washout period prior to screening: prednisone/prednisolone
for 1 month, cromolyn sodium for 2 weeks, tiotropium for 5
days, and leukotriene modifiers for 2 weeks.
Measures
ACQ
The ACQ is comprised of seven items; six are completed by
the patient. The items quantify the extent of five symptom
measures: nighttime awakenings, symptom severity upon
awakening, activity limitation due to asthma, and shortness
of breath due to asthma and wheezing within the past
week, each rated on a 7-point scale, where 0 represents no
symptoms or limitations, and 6 indicates severe symptoms
or impairment. The sixth patient-reported item counts
the past week’s use of a SABA, where 0 represents “None”
and 6 represents “More than 16 puffs most days.” The
seventh item is the clinician-assessed FEV1% predicted
scored using a 7-point scale, where 0 represents “>95%
predicted” and 6 represents “<50% predicted”.7 The self-
administered paper and pencil form of this instrument has
been validated in asthma patients age 11 years and older.12
AQLQ12D
The AQLQ(S) is a 32-item instrument developed to measure
the health-related quality of life of adults (17þ years old)
with asthma using standardized activities.8 To avoid the
need for separate measures for younger patients (age
12e16 years) and adults in asthma clinical research settings,
the AQLQ12þ was developed in 2005 and validated to
capture asthma-specific quality of life in both age groups
within a single instrument by modifying the activity limita-
tion item measuring “work-related limitations” in the
AQLQ(S) to assess “work-/school-related limitations”.10 It
contains the domains of activity limitation (11 items),
symptoms (12 items), impact of environmental stimuli
(4 items), and emotional functioning (5 items). Each item
uses the “last two weeks” recall period and is scored on
a 7-point scale, where 1 represents the worst health
option (e.g., “A very great deal of discomfort or distress”)
and 7 indicates the best health option (e.g., “No discomfort
or distress”). The AQLQ12þ total score is the mean value
of all 32 items, where a higher score indicates better
asthma-specific quality of life.10 Standard procedures for
missing ACQ and AQLQ data were used.8
Daily diary measures
After the initial screening visit, all patients were
provided instructions on the completion of a daily elec-
tronic diary that included study medication compliance,
concomitant medication use, AM & PM asthma symptoms
(wheezing, coughing and shortness of breath) and PEF
measurements, daytime & nighttime SABA use and time of
first SABA use, oral prednisone/prednisolone use, number
of nocturnal awakenings requiring SABA, and daytime &
nighttime Asthma Symptoms Diary (ASD) questions.19 The
daily daytime ASD questionnaire consists of 4 items to
capture the frequency of asthma symptoms, the perceivedinconvenience of asthma symptoms, the impact on ability
to perform usual activities, and how often asthma symp-
toms limited usual activities. The nighttime ASD item
inquires about the frequency of nighttime awakenings due
to asthma.
Asthma control guidelines
GINA
Prominent national and international asthma organizations
assert that the absence, or alternately, the reduction of
clinical manifestations of asthma, such as nighttime
awakenings, activity limitations due to asthma, use of
rescue medications, and asthma symptoms, including
wheezing, shortness of breath, represent clinically mean-
ingful outcomes in the management of asthma. GINA has
proposed an approach to differentiate patients who ach-
ieve asthma control in the clinical setting with relative ease
and minimal economic burden.3 Using the most recent GINA
criteria, trial participants were classified as “well
controlled” if there were: 2 or less reports of the presence
of daytime symptom, 2 or less rescue medication uses in
the week prior to the ACQ measurement, no activity limi-
tations, no nocturnal symptoms and awakenings, no exac-
erbations during that week, and lung functioning of
80% FEV1 predicted at the corresponding clinic visit.
Otherwise, the participant was classified as “not well
controlled”.
NHBLI
Similarly, using the NHBLI17 criteria, a participant was
classified as “well controlled” if there were: 2 or less
reports of the presence of daytime or nighttime symptom, 2
or less rescue medication uses, 2 or less nighttime awak-
enings in the week prior to the ACQ measurement, no
activity limitations during that week, and lung functioning
of >80% FEV1 predicted at the corresponding clinic visit.
Otherwise, the participant was classified as “not well-
controlled.”
Statistical analyses
Psychometric analyses
To evaluate the performance of the four versions of the
ACQ, the internal consistency reliability of each of the
four versions was examined using Cronbach’s alpha for each
ACQ version’s total score using baseline data from each trial.
Alpha results of at least 0.70 are considered acceptable
for scale use.18 Estimation of test-retest reliability required
identification of subjects with stable asthma between
baseline and Week 4. Subjects whose conditions neither
improved nor deteriorated by an AQLQ12þ score  0.5 over
this time span were placed in the stable group.6 Test-retest
reliability of the ACQ versions was determined among the
stable group using an intraclass correlation coefficient
(ICC), with values greater than 0.60 are considered accept-
able for establishing substantial test-retest reliability.13
To examine construct validity, the pattern and magni-
tude of the relationships between the ACQ versions scores
with other patient-reported outcomes (PRO) measures and
PEF scores were examined in each trial using Pearson’s
correlation coefficients for comparison with each other
(correlations between each of the four versions of the ACQ)
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baseline or during the week before baseline visit. For all
correlational analyses, the absolute value of the Pearson’s
correlation coefficients assessed whether weak (jrj < 0.30),
moderate (0.30  jrj < 0.60), or strong (jrj  0.60) rela-
tionships existed.5
Known-groups validity was examined using mean score
comparisons in each trial of the ACQ versions scores of:
those with any nighttime awakenings compared to those
with no nighttime awakenings the week before baseline;
those with daytime use of SABAs compared to those with
no daytime SABA use the week before baseline; those
with nighttime SABA use compared to those with no night-
time SABA use the week before baseline; and those with
any use of SABAs compared to those with no SABA use the
week before baseline. Due to the potential for unbalanced
comparision groups, the results from each two-sample
t-test first examined the F-test for equality of variances,
and then selected the appropriate equal or unequal vari-
ance-related p-value based on the result of the F-test.
Responsiveness of the ACQ versions was examined using
Pearson’s correlation coefficients calculated in each study
to compare for the change from baseline to 26 weeks in the
ACQ scores to the change from baseline to end of treatment
visit scores for: each version of the ACQ; the AQLQ12þ
domain and overall scores; the number of days with either
daytime or nighttime SABA use; the number of days with
nighttime awakenings; and FEV1% predicted.
Responder analyses
Within each treatment group the percentage of each study’s
participants who responded to therapy was examined using
the threshold of 1.00 as a cut point for examining “well-
controlled” vs. “not well controlled” asthma.11 For each
trial, the percentage of participants in the MFF combination
formulation treatment group achieving responder’s status
(changing from an ACQ score  1.00 at baseline to a score
less than 1.00 at 4 weeks, 12 weeks, 26 weeks and Study
Endpoint, defined as the last observation carried forward
at 26 weeks) were compared to the percentage reaching
this milestone in the other treatment groups. These anal-
yses allowed for the comparison of the proportion of asthma
patients who demonstrated an important change on the
ACQ for each dose at each evaluation time point in the
respective clinical trials across each of the four versions.
Concordance studies
Six types of concordance studies were conducted to
compare each ACQ version’s ability to measure asthma
control and control-related change using the 1.00 cut point.
All concordance methods used kappa statistics as measures
of agreement between the different ACQ versions catego-
rizations for control and those using the GINA and NHBLI
guidelines. Kappa statistics were interpreted according to
the Landis and Koch13 benchmarks of: 0.81e1.00 Z almost
perfect agreement; 0.61e0.80 Z substantial agreement;
0.41e0.60 Z moderate agreement; 0.21e0.40 Z fair
agreement; 0.0e0.20 Z poor agreement.
Four types of concordance analyses were conducted.
First, cross sectional concordances at baseline, 4 weeks,
12 weeks, 26 weeks and Study Endpoint compared results
for all ACQ versions using the 1.00 cut point to classifyparticipants as “well controlled” vs. “not well controlled.”
Next, concordance between the four versions of the ACQ
was assessed for each treatment group within each study
when trial patients who changed from “not well controlled”
at baseline to “well controlled” or stayed “not well-
controlled” at 4 weeks, 12 weeks, 26 weeks and Study
Endpoint. Third, concordance analyses examined each
ACQ version at each relevant time point and within each
treatment group and study when trial participants were
cross sectionally categorized by the 1.00 cut point using the
ACQ scores and compared to classifications by the GINA3
criteria for asthma control. These cross sectional analyses
were followed by longitudinal evaluations of the concor-
dance assessed for each treatment group (MFF, MF, F and
placebo) between the ACQ versions (using the 1.00 cut
point definition) and GINA classifications when trial patients
who changed from “not well controlled” at baseline to
“well controlled” or stayed “not well-controlled” at 4
weeks, 12 weeks, 26 weeks and Study Endpoint. Fourth and
finally, the concordance analyses conducted using the
GINA criteria were repeated using the NHBLI17 recommen-
dations for assessing asthma control to compare with the
ACQ versions using the 1.00 cut point.
Results
Sociodemographic and clinical characteristics
For patients in both the low- and medium-dose trials,
baseline characteristics indicated that the majority of
patients were Caucasian (77% and 72%, respectively) and
female (55% and 59%, respectively; Table 1). The mean age
in the low-dose study was 38.3  16.6, with 15% adolescent
participation (age 12e17 years). Lung function was
impaired with mean percent predicted FEV1 of 75%. In
the medium-dose trial, the mean age was somewhat higher
(42.3  15.4), with a lower percentage of adolescents
participation (8%) and the mean percent predicted FEV1
was 73%. The AQLQ12þ domain and overall mean scores
at baseline were similar for both trials. All four versions
of the ACQ had similar baseline mean values ranging from
1.0 to 1.4 and 1.2 to 1.6 in the low- and medium-dose
studies, respectively.
Reliability
In the low-dose study, all four versions of the ACQ demon-
strated acceptable levels (alpha  0.70) of internal consis-
tency (Table 2) with Cronbach’s alpha ranging from 0.82
(ACQ-6a) to 0.87 (ACQ-5). Test-retest reliability showed
substantial agreement (ICC > 0.60) in all four versions of
the ACQ, with ICC scores ranging from 0.75 (ACQ-7) to 0.80
(ACQ-5). For the medium-dose study, internal consistency
ranged from 0.84 (ACQ-6a) to 0.88 (ACQ-6b and ACQ-5), with
ICC scores demonstrating substantial agreement for all four
ACQ versions (0.78  ICC  0.80; Table 2).
Construct validity
Pearson’s correlations at baseline between the ACQ versions
and other indicators of asthma-specific health are shown
Table 1 Baseline sociodemographic and clinical characteristics: low- and medium-dose studies.
Variable Low-dose study (N Z 737) Medium-dose study (N Z 772)
Gender, n (%)
Male 331 (44.9%) 319 (41.3%)
Female 406 (55.1%) 453 (58.7%)
Age, n (%)
<18 110 (14.9%) 62 (8.0%)
18e64 582 (79.0%) 669 (86.7%)
65 and older 45 (6.1%) 41 (5.3%)
Race/ethnicity, n (%)
Caucasian 568 (77.1%) 555 (71.9%)
Non-Caucasian 169 (22.9%) 217 (28.1%)
Body mass index, n (%)
<25 324 (44.0%) 288 (37.3%)
25e29 231 (31.3%) 242 (31.3%)
>30 181 (24.6%) 242 (31.3%)
Missing 1.0 (0.1%) e
ACQ mean (SD)
ACQ-7 1.3 (0.7) 1.5 (0.8)
ACQ-6a 1.4 (0.8) 1.6 (0.8)
ACQ-6b 1.0 (0.8) 1.2 (0.9)
ACQ-5 1.1 (0.9) 1.3 (0.9)
AQLQ12þ subscales, mean (SD)
Activity limitation 5.8 (0.9) 5.5 (1.1)
Symptoms 5.7 (1.0) 5.4 (1.1)
Impact of environmental stimuli 5.4 (1.3) 5.0 (1.4)
Emotional function 5.8 (1.1) 5.4 (1.3)
AQLQ12þ overall score, mean (SD) 5.7 (0.9) 5.4 (1.0)
FEV1 % predicted, mean (SD) 75.3 (8.1) 72.6 (8.9)
PEF scores (SD)
AM 394.2 (121.2) 373.1 (117.3)
PM 403.7 (123.1) 379.6 (119.2)
702 K.W. Wyrwich et al.in Table 3. Because all correlations with jrj  0.08 were
statistically significant at the p < 0.05 level, only the
magnitude of the correlations are presented. All four
versions of the ACQ were strongly correlated with each
other (r  0.97 both trials). Because higher scores on the
ACQ denote worsening asthma control while higher scores
on the AQLQ12þ denote better asthma-related health, allTable 2 Internal consistency reliability and test-retest reliabili
studies.
ACQ version N Cronba
Low dose study
ACQ-7 737 0.83
ACQ-6a 737 0.82
ACQ-6b 737 0.87
ACQ-5 737 0.87
Medium dose study
ACQ-7 772 0.85
ACQ-6a 772 0.84
ACQ-6b 772 0.88
ACQ-5 772 0.88correlations with the ALQL12þ domain and overall scores
were negative. Similar and strong inverse correlations
were demonstrated between each ACQ version and the
baseline AQLQ12þ domain and overall scores in the both
the low- and medium-dose trials, with the exception of
the moderate association between the environment
domain and all four ACQ versions in the low-dose trialty of four versions of ACQ at baseline: low- and medium-dose
ch’s alpha N ICC
445 0.75
445 0.76
445 0.78
445 0.80
406 0.78
406 0.79
406 0.79
406 0.80
Comparison of four versions of the ACQ 703(0.57  r  0.55), and the ACQ-7 and ACQ-6b in the
medium-dose trial (rZ 0.59). In both trials, moderate to
strong correlations (0.57 r 0.68) were observed between
the ACQ versions and the average daytime and nocturnal
symptom diaries for the week before baseline. However,
there were weak correlations between all ACQ versions
when compared with PEF measurements in both studies,
with the ACQ-6b and ACQ-5 versions performing slightly
worse than the ACQ-7 and ACQ-6a counterparts that
included that FEV1% predicted item.
Known-groups analyses
For the low- and medium-dose trials, the mean scores from
all four versions of the ACQ were able to distinguish
between those subjects who had: any nighttime awaken-
ings vs. none; any use of daytime SABA vs. those who
had none; any use of nighttime SABA vs. those who had
none; and those who had any SABA use vs. those who had
none during the week before baseline (Table 4). For all
comparisons, the mean baseline scores for all versions of
the ACQ were higher in trial participants who experienced
asthma-associated morbidity before baseline compared to
the specific morbidity-free participants (p < 0.001 for all
comparisons).
Responsiveness
Pearson’s correlation coefficients for baseline to end-of-
treatment visit (Week 26) change scores for four versions
of the ACQ when compared with each other and other
change scores for relevant measures of asthma-related
health over the same time span are shown in Table 5. Again,
for simplicity p-values are not included, but all correlationsTable 3 ACQ versions baseline correlations with other versio
studies.
Item Low-dose study
ACQ-7 ACQ-6a
ACQ-7 e 0.99
ACQ-6a 0.99 e
ACQ-6b 0.99 0.98
ACQ-5 0.97 0.98
AQLQ12þ domains
Activity 0.69 0.69
Symptoms 0.85 0.85
Environment 0.55 0.56
Emotional 0.66 0.66
AQLQ12þ overall score 0.79 0.79
Peak expiratory flow (PEF)
AM 0.13 0.14
PM 0.12 0.13
Short-acting beta agonist use
Daytime 0.46 0.41
Nighttime 0.43 0.38
Average daytime asthma symptoms diary 0.66 0.66
Average nighttime asthma symptoms diary 0.59 0.58
Note: p< 0.05 for all correlations where jrj  0.08.with jrj  0.24 are statistically significant (p < 0.0001). In
both the low- and medium-dose studies, the change score
correlations between each ACQ version remained very high
(r  0.97). ACQ change score correlations for all versions
were also strongly correlated (jrj  0.74) with the ALQL12þ
overall change score in both studies. In both studies, the
change score correlations between changes in the number
of days with SABA used, nighttime SABA use, and nighttime
awakenings were moderate or weak (0.24  r  0.47), with
the magnitude of the relationship remaining fairly consis-
tent across all versions of the ACQ. Similarly, the correla-
tion of change in FEV1% predicted was very low (r  0.04)
for all versions of the ACQ.
Responder analyses
Applying the 1.00 cut point to the four different versions
of the ACQ, the percentage of responders who were “not
well-controlled” at baseline but subsequently crossed over
to a score less than 1.00 at follow-up visits was calculated
at 4 weeks, 12 weeks, 26 weeks, and Study Endpoint for
all four treatment groups in the low- and medium-dose
studies (Table 6). The percentages of responders for the
four versions of the ACQ for the MFF treatment group
varied at Week 4 from 36.6 to 42.0% in the low-dose study
and 24.8 to 38.6% in the medium-dose study depending on
the ACQ version. Increasingly more responders were
observed in the MFF group at 12 weeks in both studies. This
trend continued at 26 weeks for the ACQ-5 and ACQ-6a in
the low-dose study and all ACQ versions in the medium-dose
study. At Study Endpoint, there was little variation in the
percentage of responders in each of the MFF, MF and
placebo groups of the low-dose study based on the ACQ
version used. However, in the medium-dose study, thens and measures of asthma health: low- and medium-dose
Medium-dose study
ACQ-6b ACQ-5 ACQ-7 ACQ-6a ACQ-6b ACQ-5
0.99 0.97 e 0.99 0.99 0.97
0.98 0.98 0.99 e 0.98 0.98
e 0.99 0.99 0.98 e 0.99
0.99 e 0.97 0.98 0.99 e
0.70 0.70 0.67 0.68 0.68 0.69
0.86 0.86 0.82 0.83 0.83 0.84
0.57 0.57 0.59 0.59 0.60 0.61
0.68 0.67 0.64 0.64 0.65 0.65
0.81 0.81 0.77 0.78 0.78 0.80
0.09 0.09 0.16 0.16 0.13 0.12
0.08 0.08 0.15 0.16 0.12 0.12
0.46 0.40 0.32 0.29 0.31 0.28
0.42 0.37 0.34 0.30 0.33 0.29
0.68 0.68 0.64 0.64 0.66 0.65
0.60 0.59 0.57 0.56 0.58 0.57
Table 4 Known-groups analyses of the baseline ACQ scores: low- and medium-dose studies (p<0.001 for all comparisons).
N Mean baseline
ACQ-7 score (SD)
Mean baseline
ACQ-6a score (SD)
Mean baseline
ACQ-6b score (SD)
Mean baseline
ACQ-5 score (SD)
Number of nighttime awakenings
Low-dose study
0 529 1.09 (0.61) 1.20 (0.65) 0.79 (0.69) 0.86 (0.76)
1 or more 42 2.27 (0.80) 2.42 (0.87) 2.12 (0.88) 2.27 (0.99)
Medium-dose study
0 503 1.24 (0.64) 1.33 (0.68) 0.92 (0.72) 0.97 (0.78)
1 or more 59 2.31 (0.76) 2.45 (0.80) 2.12 (0.85) 2.24 (0.92)
Daytime SABA use
Low-dose study
0 400 1.07 (0.59) 1.14 (0.66) 0.71 (0.66) 0.80 (0.76)
1 or more 169 1.89 (0.75) 1.96 (0.81) 1.69 (0.87) 1.74 (0.97)
Medium-dose study
0 330 1.11 (0.64) 1.24 (0.70) 0.78 (0.73) 0.87 (0.82)
1 or more 265 1.96 (0.75) 2.04 (0.78) 1.72 (0.81) 1.77 (0.90)
Nighttime SABA use
Low-dose study
0 425 1.05 (0.60) 1.18 (0.67) 0.75 (0.67) 0.84 (0.77)
1 or more 131 1.91 (0.76) 1.99 (0.81) 1.71 (0.88) 1.77 (0.98)
Medium-dose study
0 344 1.13 (0.64) 1.26 (0.71) 0.81 (0.73) 0.90 (0.82)
1 or more 220 2.02 (1.84) 2.10 (0.79) 1.79 (0.83) 1.84 (0.91)
Baseline use of SABAs
Low-dose study
0 348 0.97 (0.57) 1.09 (0.64) 0.66 (0.64) 0.75 (0.74)
1 or more 221 1.79 (0.72) 1.88 (0.78) 1.59 (0.83) 1.65 (0.92)
Medium-dose study
0 270 1.05 (0.61) 1.18 ( 0.68) 0.72 (0.70) 0.81 (0.79)
1 or more 334 1.92 (0.70) 2.00 (0.75) 1.68 (0.79) 1.73 (0.87)
704 K.W. Wyrwich et al.Study Endpoint percentages in the MFF group varied
from 40.4% using version ACQ-6a to 54.4% with the ACQ-
6b version, and this variation in percentage of responders
based on ACQ version was observed across all four treat-
ment groups in that study (Table 6). Nonetheless, statisticalTable 5 ACQ versions change score correlations with change
studies.
Item Low-dose study
ACQ-7
change
score
correlation
ACQ-6a
change
score
correlation
ACQ-6b
change
score
correlatio
ACQ-7 e 0.99 0.98
ACQ-6a 0.99 e 0.97
ACQ-6b 0.98 0.97 e
ACQ-5 0.97 0.98 0.99
AQLQ12þ 0.78 0.78 0.80
FEV1% predicted 0.03 0.04 0.03
No. of days with either daytime
or nighttime SABA use
0.43 0.40 0.43
No. of days with nighttime
awakenings
0.47 0.47 0.47
For jrj 0.24, p<0.0001. All other correlations p>0.05.comparisons of the percentage of responders in the
medium-dose study consistently favored the treatment
benefit in the MFF over the other three treatments
(p < 0.05) across all four ACQ versions except at Week 4
using the ACQ-5.scores from other study measures: low- and medium-dose
Medium-dose study
n
ACQ-5
change
score
correlation
ACQ-7
change
score
correlation
ACQ-6a
change
score
correlation
ACQ-6b
change
score
correlation
ACQ-5
change
score
correlation
0.97 e 0.99 0.98 0.97
0.98 0.99 e 0.97 0.97
0.99 0.98 0.97 e 0.99
e 0.97 0.97 0.99 e
0.79 0.74 0.74 0.74 0.74
0.03 0.02 0.02 0.02 0.03
0.40 0.28 0.25 0.28 0.24
0.47 0.40 0.39 0.39 0.38
Table 6 Percentage of responders each treatment group using the four versions of the ACQ: low- and medium-dose studies.
Low-dose study Medium-dose study
MFF MF F Placebo p-value MFF MF F Placebo Significance
Week 4
ACQ-7 42.0% 31.6% 24.2% 15.0% b, c, e 34.6% 20.2% 16.3% 15.0% a, b, c
ACQ-6a 34.2% 28.0% 19.8% 19.5% b, c, 24.8% 16.9% 12.5% 14.5% a, b, c
ACQ-6b 41.4% 33.7% 32.3% 19.4% b, c, e 38.6% 26.2% 20.8% 24.6% a, b, c
ACQ-5 36.6% 28.7% 26.6% 21.3% e 33.6% 23.3% 19.4% 22.3% b
Week 12
ACQ-7 56.1% 34.3% 26.9% 26.6% a, b, c 41.5% 22.1% 22.3% 19.6% a, b, c
ACQ-6a 43.9% 31.3% 21.4% 29.6% a, b, c 34.4% 21.5% 19.8% 17.1% a, b, c
ACQ-6b 52.6% 47.6% 35.7% 35.7% b, c 52.9% 30.1% 29.0% 27.4% a, b, c
ACQ-5 50.0% 38.6% 29.6% 33.9% b, c, 47.6% 27.2% 28.2% 25.6% a, b, c
Week 26
ACQ-7 51.1% 43.3% 32.6% 38.2% b 48.7% 30.8% 29.3% 27.8% a, b, c
ACQ-6a 51.5% 40.4% 27.2% 36.0% b, c 44.3% 31.3% 24.7% 23.7% a, b, c
ACQ-6b 52.2% 50.0% 46.3% 35.6% 60.4% 42.5% 36.4% 40.5% a, b, c
ACQ-5 50.1% 48.0% 36.6% 35.3% 54.6% 37.5% 33.8% 36.8% a, b, c
Study Endpoint
ACQ-7 51.2% 40.0% 26.0% 26.4% b, c, d, e 44.9% 26.1% 21.0% 19.9% a, b, c
ACQ-6a 49.2% 37.8% 22.5% 25.8% b, c, d, e 40.4% 26.8% 18.6% 18.2% a, b, c
ACQ-6b 51.7% 46.1% 41.1% 24.7% c, e, f 54.4% 37.1% 25.7% 27.9% a, b, c
ACQ-5 48.5% 42.6% 32.3% 24.7% b, c, e 50.0% 33.0% 25.2% 26.3% a, b, c
a: p<0.05 for MFF vs. MF.
b: p<0.05 for MFF vs. F.
c: p<0.05 for MFF vs. placebo.
d: p<0.05 for MF vs. F.
e: p<0.05 for MF vs. placebo.
f: p<0.05 for F vs. placebo.
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Concordance of each version of the ACQ when compared
to other ACQ versions was tested at baseline, Week 4, Week
12, Week 26, and Study Endpoint for both the low- and
medium-dose studies, with the kappa results are displayed
in Table 8. For example, the two-by-two in Table 7
comparing the ACQ-7 categorizations with those using
ACQ-6a scores at baseline in the low-dose study yielded
a kappa statistic of 0.86, with only 6.1% of the trial
participants classified differently for the two ACQ versions.
Concordance was highest between the ACQ-6b and the
ACQ-5 scores at each time point with kappa values ranging
from 0.90 to 0.93 in the low-dose study and 0.88 to 0.93
in the medium-dose study. Concordance between the
ACQ-7 and ACQ-6a was also strong, yielding kappa values
ranging from 0.86 to 0.92 in the low-dose study and 0.84 to
0.90 in the medium-dose study. Concordance betweenTable 7 Example of the data used to calculate kappa
statistics in Table 8.
ACQ-6a ACQ-7
Not well controlled Well controlled
Not well controlled 474 (64.3%) 42 (5.7%)
Well controlled 3 (0.4%) 218 (29.6%)the ACQ-6a and ACQ-6b was consistently the lowest of
the compared versions at all time points in both studies,
and kappa values ranged from 0.59 at baseline in the
low-dose study, and at Week 4 and Week 26 in the medium-
dose study to 0.71 at Study Endpoint in the low-dose
study. Overall, there was substantial or near perfect
agreement across the four ACQ versions at these crucial
time points in both studies when patients were classified
using the 1.00 cut point, with the few exceptions stemming
from the ACQ-6a vs. ACQ-6b comparisons.
Next, concordance was assessed for each treatment
group (MFF, MF, F and placebo) among the ACQ versions
when trial patients who changed from “not well controlled”
at baseline to “well controlled” or stayed “not well
controlled” at 4 weeks, 12 weeks, 26 weeks and Study
Endpoint using the 1.00 cut point definition. The kappa
results are shown in Table 10. For these comparisons, two-
by-two tables like Table 9 below were created. In this
example, the changes of patients who were not well
controlled at baseline to their 4 weeks status using ACQ-7
scores were compared to those using ACQ-6a scores of
the MFF treatment group (low-dose study), yielding a kappa
of 0.78.
Concordance remained highest between the ACQ-6b
and the ACQ-5 scores at each follow-up time point with
kappa values ranging from 0.81 to 0.95 in the low-dose
study and 0.80 to 1.00 in the medium-dose study. Concor-
dance between the ACQ-7 and ACQ-6a was again the second
Table 8 Concordance (kappa values) of ACQ versions USING 1.00 cut point for classifying asthma control at baseline, week 4,
week 12, week 26 and Study Endpoint.
Low-dose study Medium-dose study
ACQ-7 ACQ-6a ACQ-6b ACQ-7 ACQ-6a ACQ-6b
Baseline
ACQ-6a 0.86 e e 0.90 e e
ACQ-6b 0.69 0.59 e 0.69 0.61 e
ACQ-5 0.75 0.64 0.91 0.71 0.63 0.93
Week 4
ACQ-6a 0.87 e e 0.84 e e
ACQ-6b 0.75 0.65 e 0.71 0.59 e
ACQ-5 0.78 0.71 0.92 0.73 0.63 0.89
Week 12
ACQ-6a 0.88 e e 0.89 e e
ACQ-6b 0.72 0.63 e 0.68 0.60 e
ACQ-5 0.77 0.69 0.90 0.71 0.64 0.92
Week 26
ACQ-6a 0.91 e e 0.89 e e
ACQ-6b 0.76 0.70 e 0.68 0.59 e
ACQ-5 0.79 0.74 0.93 0.76 0.68 0.88
Study Endpoint
ACQ-6a 0.92 e e 0.90 e e
ACQ-6b 0.77 0.71 e 0.71 0.63 e
ACQ-5 0.81 0.76 0.93 0.78 0.71 0.90
706 K.W. Wyrwich et al.highest ACQ version agreement pair, with kappa values
ranging from 0.78 to 0.97 in the low-dose study and 0.70
to 0.96 in the medium-dose study. Likewise, with two
exceptions in the placebo group at Week 12 in the low-dose
study and the F group at Week 4 in the medium-dose study,
concordance between the ACQ-6a and ACQ-6b was consis-
tently the lowest of the compared versions in all treatment
groups at all follow-up time points in both studies, and
kappa values ranged from 0.41 to 0.85 in the low-dose
study, and 0.50 to 0.71 in the medium-dose study. Overall,
there was substantial or near perfect agreement (k  0.61)
on change classifications across the four ACQ versions at
time points of 12 weeks and later, with the few exceptions
stemming from the ACQ-6a vs. ACQ-6b comparisons and
lower levels of agreement between the ACQ-5 and the ACQ-
6a in the F group at 26 weeks and the Study Endpoint.
Table 12 reports the kappa statistics for the concordance
of each ACQ version at each relevant time point and within
each treatment group and study when agreement beyond
chance was evaluated for trial participants cross sectionally
categorized by the 1.00 cut point compared to classifica-
tions by the GINA6 criteria for asthma control. For example,
when the ACQ-7 scores were examined at baseline in theTable 9 Example of the data used to calculate kappa statistics
ACQ-6a ACQ-7
Changed to we
Changed to well controlled 36 (31.3%)
Stayed not well controlled 11 (9.6%)MFF treatment group for the low-dose study, the two-by-
two table depicted in Table 11 generated a kappa value of
0.30.
In the low-dose study, the ACQ-6a version had better
concordance with the GINA criteria for classifying asthma
control that the other three ACQ versions. This was also
generally true in the medium-dose study; however, the
ACQ-7 occasionally had better agreement (e.g., Placebo
group at baseline, MFF group at Week 4). Nonetheless, the
kappa values never exceeded 0.48 (moderate agreement),
and all treatment groups had agreement estimates in the
poor range (0.00e0.20) at more than one time point in the
medium-dose study.
When concordance was assessed for each treatment
group between the ACQ versions (using the 1.00 cut point
definition) and GINA classifications when trial patients
who changed from “not well controlled” at baseline to
“well controlled” or stayed “not well controlled” at 4
weeks, 12 weeks, 26 weeks and Study Endpoint, the
kappa results shown in Table 13 were again moderate, fair
or poor (k  0.60). The ACQ-6a comparison with the GINA
classification at Week 12 in the low-dose study was the
only exception, achieving a kappa value of 0.61, and thein Table 10
ll controlled Stayed not well controlled
1 (0.9%)
67 (58.3%)
Table 10 Concordance (kappa values) of ACQ versions using 1.00 cut point for classifying change week 4, week 12, week 26
and Study Endpoint within each treatment group among study participants “Not Well-Controlled” at baseline.
Low-dose study Medium-dose study
ACQ-7 ACQ-6a ACQ-6b ACQ-7 ACQ-6a ACQ-6b
Week 4
MFF
ACQ-6a 0.78 e e 0.70 e e
ACQ-6b 0.70 0.52 e 0.73 0.51 e
ACQ-5 0.61 0.60 0.90 0.72 0.57 0.80
MF
ACQ-6a 0.83 e e 0.84 e e
ACQ-6b 0.67 0.57 e 0.58 0.50 e
ACQ-5 0.84 0.71 0.81 0.64 0.56 0.86
F
ACQ-6a 0.88 e e 0.84 e e
ACQ-6b 0.62 0.54 e 0.77 0.70 e
ACQ-5 0.72 0.64 0.84 0.75 0.65 0.91
Placebo
ACQ-6a 0.92 e e 0.87 e e
ACQ-6b 0.40 0.47 e 0.58 0.52 e
ACQ-5 0.46 0.52 0.95 0.64 0.60 0.84
Week 12
MFF
ACQ-6a 0.79 e e 0.85 e e
ACQ-6b 0.79 0.70 e 0.61 0.56 e
ACQ-5 0.79 0.74 0.95 0.63 0.58 0.88
MF
ACQ-6a 0.87 e e 0.90 e e
ACQ-6b 0.65 0.50 e 0.62 0.58 e
ACQ-5 0.78 0.66 0.80 0.69 0.65 0.94
F
ACQ-6a 0.82 e e 0.90 e e
ACQ-6b 0.66 0.50 e 0.83 0.71 e
ACQ-5 0.74 0.66 0.86 0.83 0.72 1.00
Placebo
ACQ-6a 0.97 e e 0.84 e e
ACQ-6b 0.75 0.75 e 0.64 0.50 e
ACQ-5 0.73 0.73 0.92 0.68 0.61 0.84
Week 26
MFF
ACQ-6a 0.98 e e 0.88 e e
ACQ-6b 0.74 0.71 e 0.71 0.60 e
ACQ-5 0.84 0.81 0.91 0.80 0.68 0.89
MF
ACQ-6a 0.89 e e 0.95 e e
ACQ-6b 0.74 0.66 e 0.65 0.59 e
ACQ-5 0.81 0.73 0.91 0.69 0.68 0.86
F
ACQ-6a 0.83 e e 0.84 e e
ACQ-6b 0.60 0.41 e 0.79 0.64 e
ACQ-5 0.59 0.43 0.82 0.86 0.71 0.90
Placebo
ACQ-6a 0.87 e e 0.82 e e
ACQ-6b 0.90 0.85 e 0.73 0.58 e
ACQ-5 0.96 0.87 0.95 0.85 0.66 0.85
Study Endpoint
MFF
ACQ-6a 0.93 e e 0.85 e e
ACQ-6b 0.80 0.74 e 0.74 0.61 e
(continued on next page)
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Table 10 (continued)
Low-dose study Medium-dose study
ACQ-7 ACQ-6a ACQ-6b ACQ-7 ACQ-6a ACQ-6b
ACQ-5 0.83 0.81 0.89 0.81 0.69 0.87
MF
ACQ-6a 0.91 e e 0.96 e e
ACQ-6b 0.75 0.68 e 0.64 0.59 e
ACQ-5 0.82 0.75 0.88 0.69 0.68 0.89
F
ACQ-6a 0.86 e e 0.88 e e
ACQ-6b 0.58 0.43 e 0.79 0.66 e
ACQ-5 0.60 0.48 0.81 0.85 0.73 0.92
Placebo
ACQ-6a 0.90 e e 0.82 e e
ACQ-6b 0.89 0.85 e 0.74 0.61 e
ACQ-5 0.93 0.86 0.96 0.85 0.66 0.88
Table 11 Example of the data used to calculate kappa statistics in Table 12.
ACQ-7 GINA
Well controlled Not well controlled
Well controlled 15 (8.4%) 41 (23.0%)
Not well controlled 3 (1.7%) 119 (66.9%)
Table 12 Concordance (kappa values) of ACQ versions using 1.00 cut point for classifying asthma control and 2008 GINA
Asthma control guidelines at baseline, week 4, week 12, week 26 and Study Endpoint.
Low-dose study Medium-dose study
MFF MF F Placebo MFF MF F Placebo
Baseline
ACQ-7 0.30 0.28 0.33 0.23 0.33 0.20 0.22 0.19
ACQ-6a 0.32 0.29 0.30 0.26 0.33 0.26 0.22 0.12
ACQ-6b 0.21 0.17 0.21 0.14 0.20 0.09 0.12 0.09
ACQ-5 0.22 0.19 0.22 0.15 0.21 0.09 0.13 0.08
Week 4
ACQ-7 0.33 0.32 0.39 0.39 0.28 0.25 0.27 0.30
ACQ-6a 0.41 0.37 0.46 0.46 0.26 0.26 0.31 0.19
ACQ-6b 0.24 0.25 0.28 0.27 0.20 0.10 0.20 0.14
ACQ-5 0.29 0.28 0.28 0.27 0.17 0.11 0.23 0.11
Week 12
ACQ-7 0.33 0.40 0.40 0.36 0.32 0.34 0.33 0.11
ACQ-6a 0.42 0.42 0.48 0.39 0.40 0.36 0.37 0.14
ACQ-6b 0.22 0.23 0.30 0.22 0.19 0.18 0.15 0.05
ACQ-5 0.23 0.28 0.30 0.23 0.20 0.20 0.17 0.10
Week 26
ACQ-7 0.32 0.31 0.46 0.38 0.28 0.27 0.35 0.28
ACQ-6a 0.34 0.36 0.47 0.40 0.30 0.28 0.38 0.32
ACQ-6b 0.21 0.22 0.29 0.27 0.15 0.14 0.23 0.16
ACQ-5 0.24 0.22 0.31 0.28 0.18 0.14 0.21 0.20
Study Endpoint
ACQ-7 0.30 0.37 0.40 0.45 0.27 0.29 0.38 0.29
ACQ-6a 0.34 0.41 0.43 0.46 0.32 0.30 0.39 0.28
ACQ-6b 0.21 0.27 0.25 0.34 0.16 0.13 0.29 0.19
ACQ-5 0.25 0.28 0.27 0.36 0.19 0.15 0.27 0.22
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Table 13 Concordance (kappa values) of change score classifications between ACQ versions using 1.00 cut point for classifying
asthma control and 2008 GINA asthma control guidelines at week 4, week 12, week 26 and Study Endpoint.
Low-Dose Study Medium-Dose Study
MFF MF F Placebo MFF MF F Placebo
Week 4
ACQ-7 0.28 0.34 0.31 0.17 0.20 0.19 0.11 0.15
ACQ-6a 0.31 0.36 0.43 0.30 0.13 0.33 0.23 0.13
ACQ-6b 0.25 0.34 0.23 0.27 0.12 0.16 0.10 0.08
ACQ-5 0.29 0.33 0.24 0.24 0.02 0.13 0.10 0.01
Week 12
ACQ-7 0.37 0.44 0.45 0.30 0.26 0.39 0.36 0.06
ACQ-6a 0.46 0.46 0.61 0.35 0.38 0.54 0.36 0.08
ACQ-6b 0.35 0.32 0.25 0.28 0.18 0.26 0.34 0.05
ACQ-5 0.37 0.35 0.27 0.20 0.19 0.30 0.31 0.14
Week 26
ACQ-7 0.34 0.26 0.59 0.28 0.22 0.33 0.43 0.16
ACQ-6a 0.34 0.36 0.58 0.47 0.26 0.37 0.41 0.19
ACQ-6b 0.32 0.26 0.25 0.43 0.14 0.34 0.43 0.11
ACQ-5 0.35 0.23 0.32 0.42 0.15 0.31 0.43 0.12
Study Endpoint
ACQ-7 0.32 0.31 0.46 0.34 0.22 0.33 0.46 0.24
ACQ-6a 0.33 0.39 0.51 0.55 0.29 0.37 0.44 0.18
ACQ-6b 0.29 0.26 0.17 0.47 0.15 0.23 0.47 0.15
ACQ-5 0.34 0.26 0.23 0.45 0.17 0.25 0.45 0.21
Table 14 Concordance (kappa values) of ACQ versions using 1.00 cut point for classifying asthma control and 2008 NHLBI
asthma control guidelines at baseline, week 4, week 12, week 26 and Study Endpoint.
Low-dose study Medium-dose study
MFF MF F Placebo MFF MF F Placebo
Baseline
ACQ-7 0.23 0.26 0.33 0.24 0.30 0.17 0.22 0.19
ACQ-6a 0.25 0.31 0.35 0.19 0.30 0.22 0.22 0.12
ACQ-6b 0.17 0.19 0.21 0.13 0.20 0.09 0.12 0.09
ACQ-5 0.17 0.19 0.22 0.14 0.21 0.09 0.13 0.08
Week 4
ACQ-7 0.36 0.40 0.37 0.45 0.29 0.20 0.28 0.27
ACQ-6a 0.43 0.46 0.41 0.50 0.26 0.22 0.27 0.16
ACQ-6b 0.26 0.31 0.26 0.29 0.22 0.08 0.21 0.15
ACQ-5 0.30 0.36 0.25 0.30 0.19 0.09 0.24 0.10
Week 12
ACQ-7 0.35 0.40 0.39 0.35 0.33 0.33 0.30 0.12
ACQ-6a 0.43 0.43 0.47 0.38 0.41 0.34 0.33 0.16
ACQ-6b 0.24 0.22 0.29 0.21 0.18 0.16 0.15 0.09
ACQ-5 0.25 0.27 0.29 0.22 0.19 0.19 0.17 0.10
Week 26
ACQ-7 0.36 0.34 0.52 0.40 0.32 0.27 0.35 0.26
ACQ-6a 0.38 0.37 0.53 0.41 0.36 0.28 0.39 0.34
ACQ-6b 0.24 0.24 0.33 0.28 0.18 0.14 0.23 0.15
ACQ-5 0.27 0.24 0.34 0.29 0.21 0.14 0.21 0.18
Study Endpoint
ACQ-7 0.31 0.41 0.45 0.46 0.29 0.28 0.36 0.29
ACQ-6a 0.34 0.43 0.49 0.48 0.36 0.29 0.38 0.28
ACQ-6b 0.21 0.29 0.28 0.35 0.17 0.12 0.27 0.19
ACQ-5 0.25 0.31 0.32 0.37 0.22 0.14 0.25 0.22
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710 K.W. Wyrwich et al.ACQ-6a version generally produced the highest levels of
change score classification agreement with the GINA
criteria across the time spans and treatment groups in the
low-doses study, while sharing this ranking with the ACQ-7
version in the medium-dose study.
In Table 14, concordances of each ACQ version at each
relevant time point and within each treatment group and
study when agreement beyond chance was evaluated for
trial participants cross sectionally categorized by the 1.00
cut point compared to classifications by the NHBLI17 criteria
for asthma control are reported. Like the results in Table 12
for the GINA cross sectional classifications, the ACQ-6a
version had better concordance with the NHBLI criteria for
classifying asthma control than the other three ACQ
versions in the low-dose study. This was also true again in
the medium-dose study; however, the ACQ-7 occasionally
had better agreement in most treatment groups at Week 4.
Nonetheless, these kappa values never exceeded 0.53
(moderate agreement) and all treatment groups had
agreement estimates in the poor range (0.00e0.20) at more
than one time point in the medium-dose study.
Similar to the GINA results, when concordance was
assessed for each treatment group (MFF, MF, F and placebo)
between the ACQ versions (using the 1.00 cut point defini-
tion) and NHBLI classifications when trial patients who
changed from “not well controlled” at baseline to “well
controlled” or stayed “not well controlled” at 4 weeks, 12
weeks, 26 weeks and Study Endpoint, the kappa results
shown in Table 15 were again fair, moderate or poor
(k  0.60). The ACQ-6a (Week 12) and ACQ-7 (Week 26)
comparisons with the NHBLI classification for F treatment
group in the low-dose study were the only exceptions,Table 15 Concordance (kappa values) of change score classifica
asthma control and 2008 NHBLI asthma control guidelines at wee
Low-dose study
MFF MF F Placeb
Week 4
ACQ-7 0.31 0.44 0.27 0.45
ACQ-6a 0.35 0.44 0.41 0.41
ACQ-6b 0.29 0.39 0.20 0.25
ACQ-5 0.34 0.36 0.20 0.30
Week 12
ACQ-7 0.38 0.45 0.43 0.29
ACQ-6a 0.46 0.46 0.61 0.26
ACQ-6b 0.38 0.28 0.26 0.30
ACQ-5 0.40 0.34 0.28 0.18
Week 26
ACQ-7 0.38 0.36 0.64 0.26
ACQ-6a 0.38 0.43 0.59 0.41
ACQ-6b 0.35 0.33 0.29 0.46
ACQ-5 0.38 0.32 0.30 0.40
Study Endpoint
ACQ-7 0.32 0.43 0.47 0.33
ACQ-6a 0.35 0.49 0.49 0.48
ACQ-6b 0.26 0.37 0.18 0.49
ACQ-5 0.31 0.36 0.24 0.44achieving kappa values of 0.61 and 0.64, respectively. The
ACQ-7 or the ACQ-6a versions produced the highest levels of
change score classification agreement with the NHBLI
criteria across the time spans and treatment groups in the
both studies.Discussion
This study had two objectives. First, the psychometric
properties of four versions of the ACQ were investigated in
two large Phase III trials of persistent asthma patients and
agreement regarding asthma control with each other
version using the 1.00 cut point, and secondly, agreement
of the ACQ versions with two well-accepted international
guidelines for classifying asthma controls was explored
using the trials’ data. The psychometric results for all four
versions of the ACQ were strong. All internal consistency
results were greater than the recommended 0.70 threshold,
while reproducibility between test and retest demon-
strated substantial agreement. Construct validity and
responsiveness results revealed that all versions of the
ACQ were strongly correlated with each other, as well as
most domains and the overall score from the AQLQ12þ for
both baseline scores and change scores at the end of the
both studies.
Interestingly, despite the inclusion of an item scoring
FEV1% predicted in the ACQ-7 and ACQ-6a, all of the ACQ
versions had weak correlations with AM and PM PEF at
baseline, and change in FEV1% predicted at 26 weeks. This
finding mimics the report by Wallenstein et al.21 where the
7-item ACQ had a weak correlation with FEV1% predicted attions between ACQ versions using 1.00 cut point for classifying
k 4, week 12, week 26 and Study Endpoint.
Medium-dose study
o MFF MF F Placebo
0.16 0.19 0.10 0.21
0.13 0.32 0.21 0.12
0.14 0.20 0.08 0.15
0.05 0.18 0.08 0.07
0.25 0.38 0.30 0.11
0.37 0.53 0.31 0.13
0.16 0.24 0.32 0.17
0.17 0.28 0.29 0.17
0.28 0.34 0.43 0.20
0.33 0.39 0.41 0.25
0.20 0.34 0.43 0.10
0.22 0.31 0.43 0.16
0.22 0.32 0.42 0.33
0.34 0.36 0.40 0.22
0.16 0.21 0.47 0.19
0.22 0.22 0.45 0.29
Comparison of four versions of the ACQ 711baseline among asthma patient age 12 years old or older,
and adds to the growing literature10 documenting that
single time point measures of lung function are generally
unrelated to asthma-specific quality of life and to asthma
control.
With similar psychometric properties for all four ACQ
versions, the usefulness of each of the ACQ scores for
reporting asthma-related control results were explored
through a series of analyses. First, using the 1.00 cut point,
the percent of study patients who were not well controlled
at baseline but who converted to being well controlled at
later time points was examined, and all four ACQ versions
recognized these changes in roughly similar percentages.
It should be noted that a key limitation to this investi-
gation is the 1.00 cut point for categorization of the ACQ
results into “well controlled” and “not well controlled”
classifications. Although Juniper and colleagues11 identified
this threshold as the best single crossover point, these
authors also recommend using the 0.75 or lower as the
optimal cut point for identifying patients who are “well
controlled” and 1.50 and higher as the optimal level for
ascertaining which asthma patients are “not well
controlled.” The unfortunate consequence of these optimal
thresholds is that many trial participants with scores
between 0.75 and 1.50 remain unclassified when concor-
dance and change over time are investigated. Therefore,
we chose the 1.00 threshold for these exploratory analyses.
When the four versions were compared to each other for
both cross sectional and longitudinal change classifications,
the ACQ-6b and ACQ-5 had the highest version agreements,
followed by the pairing of the ACQ-7 and ACQ-6a versions.
The AQC-6a and ACQ-6b versions, which share five symp-
toms items and differ only by the inclusion/exclusion of
FEV1% or SABA use scorings, displayed the lowest levels of
agreement across the six possible version comparisons,
although their concordances were either substantial or
moderate. Moreover, the kappa values for quantifying
agreement beyond chance often improved in the longitu-
dinal concordance analyses as the time from baseline
increased in the low-dose study.
When the four ACQversions classificationswerecompared
to the GINA and NHBLI criteria for asthma control, agree-
ments both cross sectionally and longitudinally were lower
than the comparisons previously seen among ACQ versions.
TheACQ-6a generally had the strongest agreementwith each
set of criteria across both studies, with the ACQ-7 sometimes
producing better results. The GINA criteria considers the
presence of daytime symptoms more than twice a week,
rescuemedication usesmore than twice aweek, any activity
limitations, any nocturnal symptoms and awakenings, lung
functioning of 80% FEV1 predicted and exacerbations
over the past week. Although each of these criterion appear
to measure many of the same concepts tapped in the ACQ
items, not incorporating the ACQ SABA use item (ACQ-6a)
improved agreement. This may be explained by the ACQ
item’s seven response options of none, 1e2 puffs most days,
3e4 puffs most days, 5e8 puffs most days, 9e12 puffs most
days, 13e16 puffs most days and more than 16 puffs most
days to describe SABA use over the past week. The six of the
seven response options and the most days usage far exceed
the “well controlled” limits of 2 puffs per week in the GINA
criteria. Similarly, the NHBLI criteria allow SABA use on nomore than 2 days aweek,which again, does not directly align
with the puffs most days over the past week format for the
corresponding ACQ SABA use items. Rectifying the SABA use
scale by updating this ACQ item may improve the concor-
dance when ACQ-measured asthma control is compared to
the GINA and NHBLI criteria.
Additional clues regarding another ACQ item that may
need reconsideration come from the internal consistency
results. The ACQ-7 has one more item than the ACQ-6b, but
Cronbach’s alpha results were lower in both studies for the
longer measure, not higher as expected for a measure with
more items.18 This was also true for internal consistency
estimate comparison between the ACQ-6a and the ACQ-5
indicating that the extra item in each comparison
(FEV1% predicted results transformed to the ACQ’s 0-6
response scale) did not share the strength of the relation-
ship that the other six or five items in the ACQ-6b and ACQ-
5, respectively, demonstrated. Nonetheless, the two ACQ
versions that incorporate this item (ACQ-6a and ACQ-7)
performed well as the ACQ-6b and ACQ-5, which do not
include the FEV1% predicted item.
Although the kappa values for the GINA and NHBLI were
lower than those observed when comparing the four ACQ
versions to only each other, they were not unexpected.
Juniper et al.11 had similar concordance results when
selecting the best cut point for the ACQ using a gold standard
based on then-current GINA/NIH guidelines. The positive-
and negative-predicted values are detailed in that report,
with complete count dataprovided so that two-by-two tables
can be constructed like those shown in Tables 7, 9, and 11.
The moderate kappa values of 0.53, 0.54 and 0.49 for the
ACQ-7, ACQ-6b and ACQ-5, respectively, at the 1.00 cut point
in the Juniper et al. report are similar to the values observed
in this study in Tables 12 and 14. However, the ACQ-6a item
set was not investigated in that report.11
Conclusion
The four versions of the ACQ each provide advantages
and challenges when used to measure asthma control in
clinical trials. All versions have similar and strong psycho-
metric properties. The classifications of change over time
from the ACQ-7 or the ACQ-6a using a cut point of 1.00
provided generally fair to moderate agreement with the
GINA and NHBLI criteria for asthma control status.Conflict of interest
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